Skip to content
lifestyle.bossesmag.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Black Diamond Therapeutics, Inc
Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference
May 31, 2026
Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations
May 31, 2026
Black Diamond Therapeutics to Host Webcast for Investors Highlighting Updated Results from Phase 2 Trial of Silevertinib in 1L EGFRm NSCLC
May 30, 2026
Black Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 28, 2026
Black Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC Patients at the 2026 ASCO Annual Meeting
May 26, 2026
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
May 20, 2026
Rush Street Interactive to Participate at the 21st Annual Needham Technology, Media, & Consumer Conference
May 18, 2026
Rush Street Interactive Announces Pricing of Secondary Offering of Class A Common Stock by Selling Stockholders and Concurrent Repurchase of Shares
May 16, 2026
Rush Street Interactive Announces Launch of Proposed Secondary Offering of Class A Common Stock by Selling Stockholders and Concurrent Repurchase of Shares
May 16, 2026
Rush Street Interactive Announces First Quarter 2026 Results and Raises Full Year Guidance
May 6, 2026
1
2
Next Page
→